Picture supply: Getty Photographs
Kromek Group (LSE: KMK) is an AIM-listed 10.7p penny inventory with a £72.6m market-cap. The UK-based group develops radiation detection tools for medical imaging, nuclear websites and safety screening.
It serves primarily the home and US market, primarily supplying cadmium zinc telluride-based detectors.
That’s a comparatively area of interest market, which will be each advantagous and problematic. Whereas it’s unlikely to face stiff competitors, demand for its merchandise might drop sharply if situations change.
However for now, it appears to be doing very effectively. Let’s take a better look.
Lofty development expectations
The share worth has soared 103% prior to now 12 months, pushed largely by robust H1 outcomes protecting the six months to 31 October 2025.
And analysts following the inventory don’t assume it’s performed. They count on additional development, with an formidable 12-month goal of twenty-two.5p — a 106% rise!
However is it real looking to count on the shares to double in worth once more by subsequent April?
Earlier than getting too excited, I made a decision to take a better look.
In demand
What I like about Kromek is that it truly has pretty first rate earnings visibility for a penny inventory. Its near-term income pipeline is substantial, with offers in place price upward of $20m for 2026.
This momentum’s pushed by expanded distribution in 39 new international locations throughout Europe, the Center East and Asia.
In H1 2026, it reported £15m in income — up from £3.7m — with administration guiding for £60m by 2030. That’s an formidable goal, however is it backed by proof of prevailing demand?
These notable orders and contract wins appear to counsel so:
- £4.8m orders globally.
- A $37.5m cope with Siemens Healthineers.
- A £1.7m, four-year Radiological Nuclear Detection Framework with the UK MoD.
- Further nuclear safety orders from UK/Europe, US, Japan, and Canada price £2.9m.
- Multi-year bio-security contracts within the US.
So it’s a worthwhile, rising enterprise that seems to be in excessive demand. What’s the catch?
Dangers
Micro-cap shares at all times face larger threat than bigger firms, and Komek’s no stranger to that. Provide chain points and reliance on debt are key challenges that the group has struggled with prior to now.
It nonetheless carries £4.62m in debt and desires to take care of excessive money circulate to maintain working. Any vital contract loss or delayed order might throw it off monitor. Plus, penny shares are thinly traded, which provides liquidity threat for shareholders.
Nonetheless, with £56.88m in fairness and a return on fairness (ROE) of 25%, I wouldn’t say it’s struggling.
My verdict
Penny shares at all times require a bit extra religion than larger-caps, with the excessive reward potential coming with a giant dollop of threat. As a rule, assessing them appears like making an attempt to see at the hours of darkness. However for Kromek Group, its forecast worth development’s backed by real-world use circumstances and regular demand.
Except for a gradual medical imaging orderbook, the rising risk of nuclear instability within the Center East will possible enhance demand.
Like all micro-cap, it’s not one thing to go all in on. However with rising demand and promising forecasts, it’s price contemplating as a small allocation.
